Lacopat Packung Zur Behandlungseinleitung (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels in neurons. This action stabilises hyper‑excitable neuronal membranes, reduces repetitive firing, and consequently lowers the likelihood of seizure generation, particularly in focal seizure types.

The appropriate dose of Lacopat is determined individually by a qualified prescriber based on the patient’s clinical condition, age, renal function and response to therapy. Healthcare professionals start with a low dose and titrate upward as needed, following approved prescribing guidelines.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling) and import documentation.

Lacopat (lacosamide) differs from many traditional antiepileptics such as carbamazepine or phenytoin by selectively enhancing slow inactivation of sodium channels rather than blocking fast inactivation. This mechanism may result in a distinct side‑effect profile, with fewer cognitive effects but a potential for cardiac conduction changes, making it a useful alternative for patients who do not tolerate other agents.

Lacopat should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in a bathroom or near a heat source, and keep out of reach of children.

Lacopat is taken orally. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablet unless specifically instructed.

The most serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, which may lead to arrhythmias, as well as psychiatric effects like suicidal thoughts, severe skin reactions (e.g., Stevens‑Johnson syndrome), and hypersensitivity reactions. Patients should be monitored regularly for these events, especially during dose escalation.

Lacopat should be avoided in individuals with a known hypersensitivity to lacosamide or any of its excipients, in patients with significant cardiac conduction disorders (e.g., second‑degree AV block), and in those taking contraindicated medications that markedly prolong the PR interval. A thorough medical review is essential before initiating therapy.